As the pharmaceutical and biotech industries shift their attentions from small molecule therapeutics to biologics, an increased amount of attention is being paid to the prospect of membrane proteinsas drug targets for antibodies and other protein scaffolds. For these large target classes, biologics offer improved selectivity, an alternative for targets with known function that have not been amenable to small molecules and the potential for using antibodies for the targeted delivery of therapeutics. However, for the field to advance, fundamental challenges of antigen quality, screening methodology, antibody engineering and target identification must be resolved.
This two-part meeting provides a forum in which discovery biologists and protein engineers can come together to discuss next generation strategies and technologies that will allow antibody-and alternate scaffold-based therapeutics directed against these target families to advance into the clinic and beyond.
The second conference, Generation, Preparation and Selection of Membrane Protein Targets, explores approaches to generating antigens of sufficient quality and purity to enable structural and modeling studies of target engagement and the associated screening and selection strategies used to isolate high quality binders.
Topics may include, but are not limited to:
Generation of Functional Membrane Proteins:
• Determining appropriate generation technologies for specific targets and classes
• DNA-focused immunizations and technologies
• Improving/extending genetic immunization technologies
• Display methods
• Single cell methods
• Virus-like particles (VLPs)
• Emerging alternative expression systems
Membrane Protein Stabilization and Purification:
• When should a purified protein be used as an antigen?
• Detergent strategies for stabilizing and crystallizing membrane proteins
• Chemical cross linking to stabilize membrane proteins
• The challenges of stabilizing ion channels
• Grafting of unique binding sites to mAb framework
• Stabilization of membrane proteins as targets for phage display selections
• Nanodiscs for membrane protein solubilization and reconstitution
• Optimizing proteins for structure determination
Selection and Screening:
• Labeling and non-labeling techniques to study interactions with binding partners
• Functional antibody isolation using high throughput screening technologies
• Microfluidics based screening
• Multiplexing assays for membrane protein biology and research
• Antibody optimization for membrane bound targets
Who should attend:Directors, Managers, Researchers, and Scientists from Pharmaceutical and Biotech Companies, Academic/Government research labs working in the fields of Antibody Discovery, Antibody and Protein Engineering, Biophysical Characterization, Candidate Screening, Discovery Biology, Protein Biochemistry, Structural Biology and Target Identification & Validation
If you are interested in speaking, please click here to submit a proposal.
To register for a very special early-bird discounted rate, please click here.
The deadline for submission is March 28, 2014.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For questions or suggestions about the meeting, please contact: Kent Simmons
Cambridge Healthtech Institute
T: (+1) 207-869-9199
For sponsorship and exhibit sales information including sponsored podium presentations, contact:Jon Stroup
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483